IMPACT ON SURVIVAL OF SURGICALLY DEFINED FAVORABLE RESPONSES TO SALVAGE INTRAPERITONEAL CHEMOTHERAPY IN SMALL-VOLUME RESIDUAL OVARIAN-CANCER

被引:62
作者
MARKMAN, M [1 ]
REICHMAN, B [1 ]
HAKES, T [1 ]
LEWIS, JL [1 ]
JONES, W [1 ]
RUBIN, S [1 ]
BARAKAT, R [1 ]
CURTIN, J [1 ]
ALMADRONES, L [1 ]
HOSKINS, W [1 ]
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT SURG,GYNECOL SERV,NEW YORK,NY 10021
关键词
D O I
10.1200/JCO.1992.10.9.1479
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the impact on survival of the attainment of surgically defined favorable responses (S-R) to salvage intraperitoneal (IP) chemotherapy after initial systemic cytotoxic drug delivery. Patients and Methods: We examined the survival of patients who were treated on one of three phase II IP trials that were conducted at the Memorial Sloan-Kettering Cancer Center. A total of 58 patients whose largest residual tumor masses measured ≤ 0.5 cm in maximum diameter at the initiation of this salvage therapy were assessable for response, 28 of whom (48%) demonstrated a S-R, which included 19 (33%) who achieved a surgically defined complete response (S-CR). Results: With a median follow-up of 43+ months (range, 33+ to 58+ months) from the initiation of IP therapy, 12 of 19 (63%) have recurred. The median duration of S-CR for the 10 patients with microscopic residual disease was 32 months compared with 15 months for the nine patients with macroscopic residual disease (largest tumor mass ≤ 0.5 cm; P > .1). For patients with microscopic residual disease who experienced a S-CR (n = 10) after salvage IP therapy, the median overall survival from the initiation of therapy has not been reached, but will exceed 4 years compared with a 25-month median survival for the nonresponding patients (n = 13; P = .004). The median survival for the 18 patients with small-volume macroscopic disease who responded to therapy was 40 months compared with 19 months for the nonresponders (P = .009). Conclusion: Although the results of this evaluation are encouraging and suggest that the attainment of a S-R, particularly a S-CR, after IP chemotherapy may result in a clinically meaningful favorable impact on survival, a randomized controlled trial will be required to address definitively this important issue. © 1992 by American Society of Clinical Oncology.
引用
收藏
页码:1479 / 1484
页数:6
相关论文
共 20 条
[1]  
COPELAND LJ, 1986, OBSTET GYNECOL, V68, P873
[2]  
COPELAND LJ, 1985, CANCER, V55, P472, DOI 10.1002/1097-0142(19850115)55:2<472::AID-CNCR2820550231>3.0.CO
[3]  
2-A
[4]   2ND THOUGHTS ABOUT 2ND-LOOK LAPAROTOMY IN ADVANCED OVARIAN-CANCER [J].
FRIEDMAN, JB ;
WEISS, NS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (15) :1079-1082
[5]   INFLUENCE OF SECONDARY CYTOREDUCTION AT THE TIME OF 2ND-LOOK LAPAROTOMY ON THE SURVIVAL OF PATIENTS WITH EPITHELIAL OVARIAN-CARCINOMA [J].
HOSKINS, WJ ;
RUBIN, SC ;
DULANEY, E ;
CHAPMAN, D ;
ALMADRONES, L ;
SAIGO, P ;
MARKMAN, M ;
HAKES, T ;
REICHMAN, B ;
JONES, WB ;
LEWIS, JL .
GYNECOLOGIC ONCOLOGY, 1989, 34 (03) :365-371
[6]   LONG-TERM SURVIVAL OF ADVANCED REFRACTORY OVARIAN-CARCINOMA PATIENTS WITH SMALL-VOLUME DISEASE TREATED WITH INTRAPERITONEAL CHEMOTHERAPY [J].
HOWELL, SB ;
ZIMM, S ;
MARKMAN, M ;
ABRAMSON, IS ;
CLEARY, S ;
LUCAS, WE ;
WEISS, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1607-1612
[7]   CHEMOTHERAPY OF DRUG-RESISTANT OVARIAN-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].
LAUFMAN, LR ;
GREEN, JB ;
ALBERTS, DS ;
OTOOLE, R ;
HILGERS, RD ;
YOUNG, DC ;
LIN, F ;
RIVKIN, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1374-1379
[8]  
LUESLEY D, 1988, LANCET, V2, P599
[10]  
MARKMAN M, 1986, SURG GYNECOL OBSTET, V162, P445